Science Pool

Download this fact sheet to learn more about Huntington's Disease proteome base including: 

• Strains and collection of tissues
• Deep proteome workflow
• Key findings in brain tissues and liver

Microelectrode array (MEA) is a powerful technique for the prediction of proarrhythmic liability. One of the main advantages of MEA is its ability to predict unexpected cardiac liabilities and long term chronic effects in vitro. 

In this poster, we focus on:

• the ability of the MEA platform to predict chronic long term effects including hERG trafficking
• predicting the cardiotoxicity of BMS-986094 (INX-08189), a hepatitis C therapy which caused death in its clinical trial after multiple weeks

Read our poster to learn more about our research!

LEARN MORE

Pre-incubating with inhibitor can influence inhibitory potency for some drug transporters such as OATP1B1. It is thought that this phenomenon is a consequence of the time taken for some inhibitors to accumulate inside the cell.

In this poster, we focus on:

• a comparison of a 30 min pre-incubation time with a 15 min pre-incubation time for OATP1B1
• the impact of inhibitor pre-incubation on P-gp and BCRP inhibition in a polarised cell monolayer

Read our poster to learn more about our research!

LEARN MORE

The mitochondria are a common target of drug-induced toxicity. A number of approaches are used to detect mitochondrial toxicity but how do we know which to use?

In this poster, we focus on:

• a comparison of the different methods including the glucose/galactose (glu/gal) cytotoxicity assay, high content screening (HCS) method for mitochondrial membrane potential and cytotoxicity, and the Seahorse flux analyser
• the ability of the different methods to predict mitochondrial toxicity through sensitivity, specificity and accuracy assessment
• an insight into the mechanism of mitochondrial toxicity through the Seahorse flux analyser and permeabilised cell assay.

Read our poster to learn more about our research!

LEARN MORE

Cardiac left ventricular hypertrophy is a risk factor for heart failure. Morphological (structural) effects such as cardiac hypertrophy can be drug-induced therefore it is important to identify these liabilities at an early stage of drug discovery and development.

In this poster, we focus on:

• using HCS to detect cardiac hypertrophy
• the comparison of single cell, co-culture and triculture microtissues models for predicting cardiac hypertrophy

Read our poster to learn more about our research!

LEARN MORE

Incubation times for in vitro hepatocyte stability assays are usually relatively short in order to maintain cell viability and enzymatic activity. This can limit the accuracy of clearance prediction for stable compounds. 

In this poster, we focus on:

• a comparison of three human models of in vitro clearance; the HμREL coculture model, 2D hepatocyte monoculture model and suspension hepatocyte model 
• data were scaled to predict in vivo human clearance
• the suitability of each system to accurately predict the clearance of stable compounds was assessed

Read our poster to learn more about our research!

LEARN MORE

Genotoxicity is a key concern during drug discovery and development. Clastogens and aneugens are two types of mutagens which result in chromosomal aberrations. Clastogens directly damage the chromosome causing sections of the DNA being deleted, added or rearranged (structural chromosomal aberrations). Aneugens cause an abnormal number of chromosomes (numerical chromosomal aberrations). Early stage screening of genotoxicity potential along with identification of the mechanism of action of the genotoxicity is important in reducing late stage failure.

In this poster, we focus on:

• a modified HCS assay for detecting genotoxins
• the incorporation of S9 fraction to identify metabolically activated genotoxins
• distinguishing between clastogens and aneugens

Read our poster to learn more about our research!

LEARN MORE

Rosuvastatin is used in the treatment of dyslipidemia. The drug transporter BCRP (breast cancer resistant protein) has been identified as the rate limiting barrier to rosuvastatin absorption.

In this poster, we focus on:

• whether estrone 3-sulfate can be applied as a surrogate in vitro BCRP probe substrate for predicting rosuvastatin DDI 
• a comparison of BCRP inhibition assessment using rosuvastatin or estrone 3-sulfate as probe substrate for six established BCRP inhibitors for which a clinical DDI with rosuvastatin has been characterised

Read our poster to learn more about our research!

LEARN MORE

Mitochondria are a common target for drug-induced toxicity. Several different in vitro methods exist for investigating drug-induced mitochondrial toxicity. 

In this poster, we focus on:

• a comparison of three different in vitro assays for detecting mitochondrial toxicity (Glu/Gal cytotoxicity assay, Seahorse Flux Analyser and high content imaging of mitochondrial membrane potential)
• the effect of protein binding on the mitochondrial toxicity
• recommendations for a tiered screening approach

Read our poster to learn more about our research!

LEARN MORE

In vitro 3D cell-based models are more representative of the complex in vivo microenvironment than traditional 2D monolayers. Furthermore, these models allow for long term compound exposures - more closely replicating clinical dosing strategies.

In this poster, we focus on:

• 3D human liver microtissues formed from multiple donors co-cultured with human non-parenchymal cells
• exposure of the cells to multiple doses of hepatotoxins and non-hepatotoxins
• HCS analysis of DNA structure, GSH content, ROS formation and mitochondrial function
• the impact of correcting for therapeutically relevant tissue C_max 

Read our poster to learn more about our research!

LEARN MORE